Sernova Biotherapeutics Inc (TSX:SVA)
Canada · Delayed Price · Currency is CAD 0.1600
+0.0050 (3.23%)
Jul 16, 2025, 9:46 AM EDT
Sernova Biotherapeutics Company Description
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada.
The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions.
Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability.
The comoany was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025.
Sernova Biotherapeutics Inc is headquartered in London, Canada.
Sernova Biotherapeutics Inc
| Country | Canada |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Jonathan M. Rigby |
Contact Details
Address: 700 Collip Circle London, British Columbia N6G 4X8 Canada | |
| Phone | 519 858 5184 |
| Website | sernova.com |
Stock Details
| Ticker Symbol | SVA |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | November - October |
| Reporting Currency | CAD |
| ISIN Number | CA81732W1041 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jonathan M. N. Rigby M.B.A., MBA | Interim Chair and Chief Executive Officer |
| James T. Parsons CPA-CA, MAcc | Chief Financial Officer |
| Dr. Frank Shannon M.D. | Senior Vice President of Clinical Development and Regulatory Affairs |
| David Burke | Vice President of Investor Relations |
| Marylyn Rigby | Chief Communications Officer |
| Dr. Pericles Calias Ph.D. | Chief Development Officer and Head of Research & Development |